Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

References

• Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003;19:1–10.
   PubMedGoogle Scholar
• Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2018;32(2):194–208.
   PubMed Web of Science ®Google Scholar
• Dreno B, Gollnick HP, Kang S, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29(Suppl. 4):3–11.
   PubMed Web of Science ®Google Scholar
• Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15(6):479–488.
   PubMed Web of Science ®Google Scholar
• Dreno B, Pecastaings S, Corvec S, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl. 2):5–14.
   PubMedGoogle Scholar
• Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–372.
   PubMed Web of Science ®Google Scholar
• Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20–27.
   PubMed Web of Science ®Google Scholar
• Kelhala HL, Palatsi R, Fyhrquist N, et al. IL-17/Th17 pathway is activated in acne lesions. PLOS One. 2014;9(8):e105238.
   PubMed Web of Science ®Google Scholar
• Eliasse Y, Leveque E, Garidou L, et al. IL-17(+) mast cell/T helper cell axis in the early stages of acne. Front Immunol. 2021;12:740540.
   PubMed Web of Science ®Google Scholar
• Kistowska M, Meier B, Proust T, et al. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. J Invest Dermatol. 2015;135(1):110–118.
   PubMed Web of Science ®Google Scholar
• Agak GW, Qin M, Nobe J, et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest Dermatol. 2014;134(2):366–373.
   PubMed Web of Science ®Google Scholar
• Karadag AS, Ertugrul DT, Bilgili SG, et al. Immunoregulatory effects of isotretinoin in patients with acne. Br J Dermatol. 2012;167(2):433–435.
   PubMed Web of Science ®Google Scholar
• Ebrahim AA, Mustafa AI, El-Abd AM. Serum interleukin-17 as a novel biomarker in patients with acne vulgaris. J Cosmet Dermatol. 2019;18(6):1975–1979.
   PubMed Web of Science ®Google Scholar
• Singh A, Khurana A, Sardana K, et al. Correlation of serum 25-hydroxy vitamin D and interleukin-17 levels with disease severity in acne vulgaris. Indian J Dermatol. 2021;66(3):291–296.
   PubMed Web of Science ®Google Scholar
• Kelhala HL, Fyhrquist N, Palatsi R, et al. Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation. Exp Dermatol. 2016;25(6):477–478.
   PubMed Web of Science ®Google Scholar
• Bocquet-Tremoureux S, Corvec S, Khammari A, et al. Acne fulminans and Cutibacterium acnes phylotypes. J Eur Acad Dermatol Venereol. 2020;34(4):827–833.
   PubMed Web of Science ®Google Scholar
• Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther. 2021;11(4):1129–1139.
   Web of Science ®Google Scholar
• Thiboutot DM, Layton AM, Anne Eady E. IL-17: a key player in the P. acnes inflammatory cascade? J Invest Dermatol. 2014;134(2):307–310.
   PubMed Web of Science ®Google Scholar
• Kaul M, Jarvis P, Rozenberg I, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35(5):1143–1151.
   PubMed Web of Science ®Google Scholar
• Fleischer AB Jr., Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78(4 Suppl.):21–31.
   PubMed Web of Science ®Google Scholar
• Tan JK, Tang J, Fung K, et al. Development and validation of a Comprehensive Acne Severity Scale. J Cutan Med Surg. 2007;11(6):211–216.
   PubMed Web of Science ®Google Scholar
• Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–832.
   PubMed Web of Science ®Google Scholar
• Dagnelie MA, Corvec S, Saint-Jean M, et al. Cutibacterium acnes phylotypes diversity loss: a trigger for skin inflammatory process. J Eur Acad Dermatol Venereol. 2019;33(12):2340–2348.
   PubMed Web of Science ®Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med. 2006;84(1):75–87.
   PubMed Web of Science ®Google Scholar
• Carrasco D, Stecher M, Lefebvre GC, et al. An open label, phase 2 study of MABp1 monotherapy for the treatment of acne vulgaris and psychiatric comorbidity. J Drugs Dermatol. 2015;14(6):560–564.
   PubMed Web of Science ®Google Scholar
• Announces encouraging interim results from gevokizumab phase 2 study for moderate to severe acne vulgaris; 2013 [Internet]. Available from: https://www.servier.ch/de/aktuell/news-detail/2/xoma-announces-encouraging-interim-results-from-gevokizumab-phase-2-study-for-moderate-to-severe-acne-vulgaris/
   Google Scholar
• Farag AGA, Maraee AH, Rifaat Al-Sharaky D, et al. Tissue expression of IL-17A and FOXP3 in acne vulgaris patients. J Cosmet Dermatol. 2021;20(1):330–337.
   PubMed Web of Science ®Google Scholar
• Abd-Elmaged WM, Nada EA, Hassan MH, et al. Lesional and circulating levels of interleukin-17 and 25-hydroxycholecalciferol in active acne vulgaris: correlation to disease severity. J Cosmet Dermatol. 2019;18(2):671–676.
   PubMed Web of Science ®Google Scholar
• Chronnell CM, Ghali LR, Ali RS, et al. Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J Invest Dermatol. 2001;117(5):1120–1125.
   PubMed Web of Science ®Google Scholar
• Aksoy G, Adisen E, Erdem O, et al. Comparison of efficacy of doxycycline and isotretinoin on cutaneous human beta-defensin-1 and -2 levels in acne vulgaris. Indian J Dermatol. 2018;63(5):380–385.
   PubMed Web of Science ®Google Scholar
• Borovaya A, Dombrowski Y, Zwicker S, et al. Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Arch Dermatol Res. 2014;306(8):689–700.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Sniukiene V, Berk DR, et al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol. 2018;17(3):333–338.
   PubMed Web of Science ®Google Scholar
• Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987–996.
   PubMed Web of Science ®Google Scholar